Johnson & Johnson’s nasal antidepressant Spravato is now generating blockbuster revenue, approaching $1.7 billion a year after rapid uptake. The drug pulled in $414 million in Q2 2025, up 53% from a year earlier, and J&J says more than 200,000 patients have received treatment. Regulators expanded indications in January 2025 to allow Spravato as a standalone therapy for treatment-resistant depression, a change clinicians and investors say has driven broader adoption. The sales surge has pushed Spravato into the centre of a wider rethink about how psychedelic-derived medicines could be commercialised.

Sales leap and the numbers behind them

Spravato’s sales growth has been sharp. The drug earned $414 million in Q2 2025, which Johnson & Johnson reported was a 53% rise from Q2 2024. J&J has said the medicine’s annual sales are nearing $1.7 billion, a milestone it first crossed in 2024. The company also reported $734 million in revenue for the first six months of 2025, up 48% versus the same period a year earlier.

Those figures come as J&J pushes clinical access. The nasal spray is available at roughly 3,000 certified outpatient centres in the United States. J&J has said the drug has treated more than 200,000 patients since approval, a tally the company shared on an investor call.

Analysts have been tracking the trend closely. Jefferies analyst Andrew Tsai said Spravato’s rapid sales support the idea that psychedelic-based therapies can be commercially workable in mental health. The market response has also helped Johnson & Johnson offset pressure from other parts of its portfolio that face patent expiries.

From party drug to prescribed treatment

Ketamine has a complex history. It was first approved in the 1970s for use as an anaesthetic. Its dissociative effects later led to recreational use and regulation concerns.

But in recent years clinicians pursued ketamine’s psychiatric potential, and commercial derivatives followed.

Spravato uses esketamine, a close chemical cousin of ketamine. Regulators first approved the nasal spray in 2019 for treatment-resistant depression, under strict administration and monitoring rules. In January 2025 the FDA expanded the label to allow Spravato as a standalone therapy for treatment-resistant depression, removing the previous requirement that patients take an oral antidepressant at the same time. That label change has been tied to faster uptake by physicians.

Clinicians who use the drug say careful implementation has been key. Jessica Moore, Johnson & Johnson’s head of investor relations, told investors the sales acceleration reflects “increased physician and patient confidence” after five years of real-world experience. Dr Gregory Mattingly, who has treated thousands of patients with the spray, said it offers some patients relief from side effects associated with traditional antidepressants and a faster response in certain cases.

Mastheads

How J&J built the market

Commercialising a medicine with ketamine’s reputation required multiple moves. J&J invested in training, observation protocols and a certified network of treatment centres to manage patient safety and monitoring. Those requirements aim to limit diversion and misuse while giving psychiatrists a controlled setting to deliver the therapy.

At the same time, the company backed promotion to clinicians. One healthcare newsletter’s analysis of J&J’s accounts noted that the company reported large selling, general and administrative expenses in 2025. The Innovative Medicine segment recorded SG&A of about $11.4 billion in 2025, and company-wide SG&A reached $23.7 billion, according to the analysis. The newsletter argued those numbers reflect a wide-ranging commercial effort that likely includes physician detailing, conferences and digital campaigns, though it didn't provide a Spravato-specific marketing spend figure.

J&J’s approach shows how a large firm can turn an unconventional compound into a structured medical offering. This network of certified treatment sites and training for providers has been central to that shift. That infrastructure also addresses payer concerns by standardising observation and safety practices.

Clinical uptake and payer coverage

Uptake among clinicians has been steady. Growth in prescription numbers has coincided with more providers gaining comfort using the nasal spray. That comfort traces to accumulating data and to the regulatory change allowing standalone use, which removed a barrier for some patients.

Insurers have been part of the story. Spravato’s commercial footprint and label expansion have helped persuade some payers to cover the therapy for specific patient groups. The visibility of a large pharmaceutical company running rigorous protocols also appears to have reassured payers and hospital systems about safety and oversight.

Still, mental health professionals advise caution. Dr Ben Yudkoff, a psychiatrist and Harvard Medical School instructor who co-founded a ketamine therapy clinic, said there's healthy tension between ketamine’s street reputation and its potential as a medical treatment. He noted the need to balance patient access with guardrails against misuse. That caution has influenced how clinics operate and how insurers evaluate long-term coverage.

Spravato’s revenue run has broader implications for investors in mental health and psychedelic-derived therapies. For one, the drug provides proof of concept that compounds with unconventional pasts can reach mainstream prescribing when packaged with safety measures and commercial muscle. That has encouraged venture and equity interest in other companies developing psychedelic treatments.

Investors are also looking at return on commercial investment. The healthcare newsletter’s analysis pointed out that J&J’s SG&A is many times larger than Spravato’s current annual sales. That makes people wonder about how much of the companywide promotional effort directly supports the nasal spray, and whether similar returns are achievable for smaller players without a global sales platform.

For Johnson & Johnson, Spravato helps diversify revenue as older drugs face patent cliffs. The company has given a wide sales range for annual potential revenues, and analysts now treat Spravato as a key growth asset in the neuroscience roster.

Spravato’s rollout has provided an operational template. The drug’s certification model, supervised administration and real-world data have been cited by clinicians and analysts as a model for how other psychedelic-derived medicines might be delivered safely at scale. Observational protocols and physician training programs have reduced some payer resistance and offered a framework for third-party reimbursement.

At the same time, regulators and clinicians continue to weigh Balancing clinical benefit and potential for harm if treatments are used outside controlled settings. That concern shapes licensing, certification and monitoring rules that now apply to Spravato and that may appear in guidance for future therapies.

Related Articles

Spravato pulled in $414 million in Q2 2025 and nears $1.7bn.

This article was created with AI assistance.